Valuation: Aligos Therapeutics, Inc.

Market Cap 32.28M 28.12M 26.61M 24.18M 45.17M 3.09B 45.4M 317M 123M 1.57B 121M 119M 5.03B P/E 2026 *
-0.8x
P/E 2027 * -0.96x
Enterprise Value -1.32M -1.15M -1.09M -990K -1.85M -127M -1.86M -12.98M -5.02M -64.33M -4.96M -4.85M -206M EV / Sales 2026 *
-0.04x
EV / Sales 2027 * -57.2x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week-2.49%
Current month-13.14%
1 month-24.70%
3 months-3.60%
6 months-26.76%
Current year-45.39%
1 week 4.82
Extreme 4.82
5.44
1 month 4.82
Extreme 4.82
7.72
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Free

Chief Technology Officer

23,310 0.4354%
9/3/26 Free

Controller/Auditor

9,450 0.1765%
9/3/26 Free

Chief Executive Officer

105,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-2.49%-49.05%-74.55% 32.28M
+0.53%+3.35%+0.96%+29.39% 46.18B
-0.57%+2.08%+40.49%+27.64% 44.35B
-2.39%-4.44%+330.63%+529.58% 42.21B
-0.69%+1.51%+2.58%+68.37% 40.19B
+1.75%-0.28%+12.42%+41.11% 29.83B
-0.43%+4.27%+22.05%+124.33% 17.17B
+0.81%-8.95% - - 15.7B
+0.57%+9.39%+23.59%+40.57% 15.32B
-1.71%-1.64%-7.19%-36.69% 13.09B
Average -0.31%+1.28%+41.83%+83.31% 26.41B
Weighted average by Cap. -0.32%+1.73%+68.10%+125.56%

Financials

2026 *2027 *
Net sales 35.99M 31.35M 29.67M 26.96M 50.36M 3.45B 50.61M 353M 137M 1.75B 135M 132M 5.61B 4.65M 4.05M 3.83M 3.48M 6.51M 445M 6.54M 45.66M 17.65M 226M 17.47M 17.08M 725M
Net income -79.34M -69.11M -65.41M -59.43M -111M -7.6B -112M -779M -301M -3.86B -298M -291M -12.36B -125M -109M -103M -93.54M -175M -11.96B -176M -1.23B -474M -6.08B -469M -459M -19.46B
Net Debt -33.61M -29.27M -27.7M -25.17M -47.02M -3.22B -47.25M -330M -128M -1.64B -126M -123M -5.24B -298M -260M -246M -223M -417M -28.56B -419M -2.93B -1.13B -14.51B -1.12B -1.1B -46.46B
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
18/09/26 US$5.090 -1.55% 4,958
17/09/26 US$5.170 +2.38% 21,705
16/09/26 US$5.050 +1.20% 41,651
15/09/26 US$4.990 -0.99% 34,487
14/09/26 US$5.040 -3.45% 28,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.170USD
Average target price
52.38USD
Spread / Average Target
+913.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!